Metopirone

Drug overview for METOPIRONE (metyrapone):

Generic name: METYRAPONE (me-TIR-a-pone)
Drug class:
Therapeutic class: Diagnostic Agents

No enhanced Introduction information available for this drug.

No enhanced Uses information available for this drug.

DRUG IMAGES

METOPIRONE 250 MG CAPSULE

The following indications for METOPIRONE (metyrapone) have been approved by the FDA:

Indications:
Diagnostic test for secondary adrenocortical insufficiency

Professional Synonyms:
Diagnostic exam for secondary adrenocortical insufficiency
Diagnostic test for relative adrenocortical suppression

The following drug interaction information is available for METOPIRONE (metyrapone):

Contraindicated
Severe
Moderate

There are 0 contraindications.

There are 3 severe interactions. These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.

Drug Interaction	Drug Names
Metyrapone/Hydantoins SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Hydantoin increases the first pass metabolism of metyrapone. CLINICAL EFFECTS: The effect of the metyrapone test may be invalidated. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Discontinue or avoid phenytoin administration prior to metyrapone administration for pituitary-adrenal axis assessment. It may be necessary to administer metyrapone intravenously or to double its dose in patients receiving phenytoin. DISCUSSION: Invalid results to the metyrapone test have been obtained in patients receiving standard dose of metyrapone and chronic phenytoin treatment. Doubling the dose of metyrapone or administering metyrapone intravenously have produced valid results.	CEREBYX, DILANTIN, DILANTIN-125, FOSPHENYTOIN SODIUM, PHENYTEK, PHENYTOIN, PHENYTOIN SODIUM, PHENYTOIN SODIUM EXTENDED
Metyrapone/Cyproheptadine SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Cyproheptadine-induced decrease in ACTH response to metyrapone. CLINICAL EFFECTS: Decreased pituitary-adrenal response to metyrapone. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Discontinue or avoid cyproheptadine administration prior to metyrapone administration for pituitary-adrenal axis assessment. DISCUSSION: Decreased pituitary-adrenal response to metyrapone occurred during concomitant administration of cyproheptadine.	CYPROHEPTADINE HCL
Sodium Iodide I 131/Myelosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Sodium iodide I 131 can cause depression of the hematopoetic system. Myelosuppressives and immunomodulators also suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of sodium iodide I 131 with agents that cause bone marrow depression, including myelosuppressives or immunomodulators, may result in an enhanced risk of hematologic disorders, including anemia, blood dyscrasias, bone marrow depression, leukopenia, and thrombocytopenia. Bone marrow depression may increase the risk of serious infections and bleeding.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of sodium iodide I 131 states that concurrent use with bone marrow depressants may enhance the depression of the hematopoetic system caused by large doses of sodium iodide I 131.(1) Sodium iodide I 131 causes a dose-dependent bone marrow suppression, including neutropenia or thrombocytopenia, in the 3 to 5 weeks following administration. Patients may be at increased risk of infections or bleeding during this time. Monitor complete blood counts within one month of therapy. If results indicate leukopenia or thrombocytopenia, dosimetry should be used to determine a safe sodium iodide I 131 activity.(1) DISCUSSION: Hematologic disorders including death have been reported with sodium iodide I 131. The most common hematologic disorders reported include anemia, blood dyscrasias, bone marrow depression, leukopenia, and thrombocytopenia.(1)	HICON, SODIUM IODIDE I-131

There are 0 moderate interactions.

Contraindication List
Primary adrenocortical insufficiency

The following adverse reaction information is available for METOPIRONE (metyrapone):

Overview
Severe
Less Severe

Adverse reaction overview.

No enhanced Common Adverse Effects information available for this drug.

There are 9 severe adverse reactions.

More Frequent	Less Frequent
Leukopenia	Allergic dermatitis Skin rash

Rare/Very Rare
Anemia Bone marrow depression Clitoral hypertrophy Edema Hypokalemia Thrombocytopenic disorder

There are 14 less severe adverse reactions.

More Frequent	Less Frequent
Dizziness Drowsy Headache disorder Hypotension Nausea Vomiting	Acute abdominal pain Sedation

Rare/Very Rare
Acute cognitive impairment Alopecia Anorexia Hirsutism Hyperhidrosis Worsening acne

The following precautions are available for METOPIRONE (metyrapone):

Pediatric
Pregnant
Lactation
Geriatric

No enhanced Pediatric Use information available for this drug.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

No enhanced Pregnancy information available for this drug.

No enhanced Lactation information available for this drug.

No enhanced Geriatric Use information available for this drug.